Cereno Scientific’s expands the patent protection for CS1 in the US
Cereno Scientific (XSAT: CRNO B) today announced that two new patents have been granted in drug candidate CS1’s second and third patent families, respectively, in the US. This strengthens and broadens the intellectual property right (IPR) for Cereno’s Phase II drug candidate CS1 which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).“We are pleased that our continuous work in securing a strong IPR portfolio has resulted in yet another expansion of CS1’s patent protection. The US is a particularly important market and, thus, the expanded patent